In brief
A recent Consumer NZ test found that 70 percent of popular sunscreens fail to deliver the Sun Protection Factor (SPF) claimed on their labels. While all products met broad‑spectrum standards, only three matched their advertised SPF, with a top‑priced SPF 50 shaving to just SPF 14. The results highlight gaps in regulatory oversight and the importance of regular, independent lab verification.
A recent independent test by Consumer NZ found that 7 out of 10 widely available sunscreens do not achieve the Sun Protection Factor (SPF) indicated on their labels, with one product marked as SPF50 delivering only SPF14 in laboratory conditions. The study, announced on October 30, 2026, highlights a disconnect between marketing claims and actual performance, despite all entries meeting broad‑spectrum protection standards.
The consumer‑advocacy group sampled ten sunscreens, ranging from $4 to $76 per 100 ml, and used internationally recognised photochemical testing to assess UV‑B absorption. While the products all qualified as broad‑spectrum—meaning they protect against both UVA and UVB rays—only three met the exact SPF values they advertised, demonstrating a systematic over‑statement in labeling.
“New Zealand has one of the highest skin cancer and melanoma rates in the world,” said Belinda Castles, a researcher with Consumer NZ.
New Zealand has one of the highest skin cancer and melanoma rates in the world.
Castles emphasized that sunscreen plays a critical role in preventing skin cancer, and the findings underline the necessity of regular, independent testing. “There are no rules specifying how often sunscreens must be tested,” she added, pointing out that earlier investigations by the group revealed some companies relying on test reports that were several years old.
The seven sunscreens that failed to meet their label claims include a premium, high‑priced option that, in laboratory conditions, offered protection equivalent to an SPF14 product. The test data indicated that the same high‑priced product, which consumers might assume provides superior defense against ultraviolet radiation, falls far short of the protection level implied by its label designation.
Consumer NZ’s testing protocol mirrors the EU’s and the United States’ standards, which involve measuring the inertial absorbance of sunscreen chemicals under controlled UVB exposure. The study also found that six of the ten tested products still provided high protection, missing the label claim by a smaller margin but still falling short of the marketed numbers.
Analysts note that SPF numbers are calculated by measuring the reduction of UVB skin damage in vitro, and a higher SPF indicates a greater level of protection. For example, an SPF14 product theoretically reduces UVB exposure by about 93 percent, whereas SPF50 is often interpreted as offering protection of about 98 percent. The gap found in the tested product translates to a significant drop in real‑world protection.
Regulatory agencies in New Zealand monitor safety and efficacy of sunscreens, yet the study demonstrates a lack of longitudinal accountability. Unlike the stricter EU labeling system where the effective SPF must be verified within a specific timeframe of product manufacture, New Zealand currently has no mandatory periodic re‑testing clause. This gap means that even after a product passes initial certification, its claimed protection can erode over time due to ingredient degradation or manufacturing variances.
Consumer NZ’s findings arrive amid broader industry scrutiny. Prior to this study, the group had highlighted that some sunscreen manufacturers had relied on test reports older than five years, potentially jeopardising consumer safety. The current test reaffirms the necessity of keeping label claims linked to up‑to‑date analytical proof.
In response to the findings, several manufacturers are exploring third‑party verification programmes, and policymakers are considering whether the existing framework should be amended to require scheduled re‑testing or “independent verification” at set intervals. If such measures are enacted, consumers could gain confidence that the label accurately reflects the product’s real‑world protective capability.
As New Zealand grapples with the highest skin cancer incidence in the world, precise labeling becomes more critical. Misrepresentation of SPF could lead to over‑reliance on insufficient protection, potentially increasing the population’s risk of sun‑related illnesses. Consequently, the study’s implications resonate beyond the laboratory, urging a shift toward more transparent and reliable sunscreen standards.
